Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions
CLDX Stock Forecast
Celldex Therapeutics stock forecast is as follows: an average price target of $49.33 (represents a 17.87% upside from CLDX’s last price of $41.85) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CLDX Price Target
The average price target for Celldex Therapeutics (CLDX) is $49.33 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $27.00. This represents a potential 17.87% upside from CLDX's last price of $41.85.
CLDX Analyst Ratings
According to 4 Wall Street analysts, Celldex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CLDX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Celldex Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | Alex Thompson | Stifel Nicolaus | $58.00 | $34.91 | 66.14% | 38.59% |
| Nov 10, 2023 | Derek Archila | Wells Fargo | $27.00 | $25.78 | 4.73% | -35.48% |
| Nov 11, 2022 | - | Guggenheim | $63.00 | $39.89 | 57.93% | 50.54% |
The latest Celldex Therapeutics stock forecast, released on Jun 17, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $58.00, which represents a 66.14% increase from the stock price at the time of the forecast ($34.91), and a 38.59% increase from CLDX last price ($41.85).
Celldex Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $42.50 |
| Last Closing Price | $41.85 | $41.85 | $41.85 |
| Upside/Downside | -100.00% | -100.00% | 1.55% |
In the current month, the average price target of Celldex Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Celldex Therapeutics's last price of $41.85. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 09, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 12, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Jul 30, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 16, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Jun 10, 2024 | Wolfe Research | - | Outperform | Initialise |
| Jun 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Celldex Therapeutics's last stock rating was published by H.C. Wainwright on Sep 09, 2024. The company gave CLDX a "Underperform" rating, the same as its previous rate.
Celldex Therapeutics Financial Forecast
Celldex Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.13M | $1.52M | $268.00K | $967.00K | $1.61M | $407.00K | - | $174.00K | $334.00K | $153.00K | $3.48M | $685.00K | $3.79M | $668.00K | $236.00K | $2.73M | $887.00K | $546.00K | $715.00K | $1.43M | $941.00K | $2.76M |
| Avg Forecast | $650.00K | $650.00K | $650.00K | $650.00K | $1.06M | $1.07M | $854.29K | $809.00K | $1.44M | $583.33K | $528.00K | $410.00K | $264.00K | $360.00K | $400.00K | $560.00K | $1.04M | $1.22M | $643.33K | $965.00K | $600.00K | $395.00K | $800.00K | $990.00K | $815.00K | $1.26M | $1.26M | $1.26M | $3.53M | $3.51M |
| High Forecast | $650.00K | $650.00K | $650.00K | $650.00K | $1.06M | $1.73M | $854.29K | $809.00K | $1.80M | $583.33K | $528.00K | $410.00K | $264.00K | $360.00K | $400.00K | $622.22K | $1.15M | $1.36M | $714.81K | $1.07M | $666.67K | $438.89K | $888.89K | $1.10M | $905.55K | $1.40M | $1.40M | $1.40M | $4.23M | $4.22M |
| Low Forecast | $650.00K | $650.00K | $650.00K | $650.00K | $1.06M | $746.03K | $854.29K | $809.00K | $1.07M | $583.33K | $528.00K | $410.00K | $264.00K | $360.00K | $400.00K | $497.78K | $920.89K | $1.09M | $571.85K | $857.78K | $533.33K | $351.11K | $711.11K | $880.00K | $724.44K | $1.12M | $1.12M | $1.12M | $2.82M | $2.81M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | 2.87% | 2.60% | 0.51% | 2.36% | 6.11% | 1.13% | - | 0.31% | 0.32% | 0.13% | 5.41% | 0.71% | 6.31% | 1.69% | 0.29% | 2.76% | 1.09% | 0.43% | 0.57% | 1.13% | 0.27% | 0.79% |
Celldex Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $809.00K, with a low forecast of $809.00K, and a high forecast of $809.00K. CLDX's average Quarter revenue forecast represents a -80.42% decrease compared to the company's last Quarter revenue of $4.13M (Dec 23).
Celldex Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | $-32.17M | $-38.26M | $-30.50M | $-35.58M | $-29.28M | $-27.94M | - | $-23.73M | $-20.25M | $-17.02M | $-12.23M | $-15.00M | $3.07M | $-12.28M | $-13.59M | $-11.48M | $-13.75M | $-15.29M | $-13.62M | $-10.65M | $-21.32M | $-31.21M |
| Avg Forecast | $-650.00K | $-650.00K | $-650.00K | $-650.00K | $-1.06M | $-1.07M | $-854.29K | $-17.71M | $-1.44M | $-583.33K | $-528.00K | $-18.95M | $-264.00K | $-16.50M | $-400.00K | $-20.26M | $-18.91M | $-17.65M | $-14.50M | $-965.00K | $-600.00K | $-13.36M | $-11.51M | $-11.14M | $-815.00K | $-11.30M | $-13.62M | $-12.26M | $-10.00M | $-18.72M |
| High Forecast | $-650.00K | $-650.00K | $-650.00K | $-650.00K | $-1.06M | $-746.03K | $-854.29K | $-14.17M | $-1.07M | $-583.33K | $-528.00K | $-15.16M | $-264.00K | $-13.20M | $-400.00K | $-16.21M | $-15.13M | $-14.12M | $-11.60M | $-857.78K | $-533.33K | $-10.69M | $-9.20M | $-8.91M | $-724.44K | $-9.04M | $-10.90M | $-9.81M | $-8.00M | $-14.97M |
| Low Forecast | $-650.00K | $-650.00K | $-650.00K | $-650.00K | $-1.06M | $-1.73M | $-854.29K | $-21.26M | $-1.80M | $-583.33K | $-528.00K | $-22.73M | $-264.00K | $-19.80M | $-400.00K | $-24.31M | $-22.69M | $-21.18M | $-17.40M | $-1.07M | $-666.67K | $-16.04M | $-13.81M | $-13.36M | $-905.55K | $-13.56M | $-16.35M | $-14.72M | $-12.00M | $-22.46M |
| Surprise % | - | - | - | - | - | - | - | - | 22.32% | 65.59% | 57.77% | 1.88% | 110.92% | 1.69% | - | 1.17% | 1.07% | 0.96% | 0.84% | 15.54% | -5.11% | 0.92% | 1.18% | 1.03% | 16.87% | 1.35% | 1.00% | 0.87% | 2.13% | 1.67% |
10 analysts predict CLDX's average Quarter EBITDA for Mar 21 to be $-965.00K, with a high of $-857.78K and a low of $-1.07M. This is -131.45% lower than Celldex Therapeutics's previous annual EBITDA (Dec 20) of $3.07M.
Celldex Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 7 |
| Net Income | - | - | - | - | - | - | - | - | $-50.25M | $-38.26M | $-30.50M | $-22.41M | $-23.69M | $-24.96M | - | $-21.56M | $-19.27M | $-20.45M | $-13.76M | $-17.30M | $-21.90M | $-14.22M | $-11.03M | $-12.61M | $-6.00M | $-11.41M | $-11.78M | $-17.24M | $-7.24M | $-16.41M |
| Avg Forecast | $-52.82M | $-52.49M | $-51.49M | $-50.50M | $-46.29M | $-44.67M | $-38.80M | $-18.36M | $-48.44M | $-44.89M | $-43.46M | $-19.64M | $-38.95M | $-16.94M | $-27.08M | $-21.00M | $-19.67M | $-18.11M | $-15.38M | $-17.95M | $-19.08M | $-14.22M | $-12.55M | $-12.27M | $-46.83M | $-12.64M | $-15.10M | $-13.31M | $-11.30M | $-19.92M |
| High Forecast | $-52.82M | $-52.49M | $-51.49M | $-50.50M | $-46.29M | $-39.49M | $-38.80M | $-14.69M | $-35.06M | $-44.89M | $-43.46M | $-15.71M | $-38.95M | $-13.55M | $-27.08M | $-16.80M | $-15.73M | $-14.49M | $-12.30M | $-15.36M | $-16.32M | $-11.38M | $-10.04M | $-9.82M | $-40.06M | $-10.11M | $-12.08M | $-10.65M | $-9.04M | $-15.94M |
| Low Forecast | $-52.82M | $-52.49M | $-51.49M | $-50.50M | $-46.29M | $-48.56M | $-38.80M | $-22.03M | $-58.00M | $-44.89M | $-43.46M | $-23.56M | $-38.95M | $-20.32M | $-27.08M | $-25.20M | $-23.60M | $-21.74M | $-18.45M | $-20.54M | $-21.83M | $-17.07M | $-15.06M | $-14.72M | $-53.59M | $-15.16M | $-18.12M | $-15.97M | $-13.56M | $-23.91M |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 0.85% | 0.70% | 1.14% | 0.61% | 1.47% | - | 1.03% | 0.98% | 1.13% | 0.89% | 0.96% | 1.15% | 1.00% | 0.88% | 1.03% | 0.13% | 0.90% | 0.78% | 1.30% | 0.64% | 0.82% |
Celldex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Celldex Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 7 |
| SG&A | - | - | - | - | - | - | - | - | $8.83M | $8.22M | $7.22M | $6.64M | $6.60M | $6.53M | - | $6.91M | $6.24M | $5.82M | $4.31M | $4.12M | $3.62M | $3.64M | $3.53M | $3.67M | $3.22M | $3.40M | $3.91M | $4.90M | $3.72M | $5.62M |
| Avg Forecast | $3.47M | $3.47M | $3.47M | $3.47M | $5.67M | $5.74M | $4.56M | $4.32M | $7.70M | $3.12M | $2.82M | $2.19M | $1.41M | $1.92M | $2.14M | $2.99M | $5.53M | $6.53M | $3.44M | $5.15M | $3.20M | $2.11M | $4.27M | $5.29M | $4.35M | $6.73M | $6.73M | $6.73M | $18.84M | $18.76M |
| High Forecast | $3.47M | $3.47M | $3.47M | $3.47M | $5.67M | $9.24M | $4.56M | $4.32M | $9.62M | $3.12M | $2.82M | $2.19M | $1.41M | $1.92M | $2.14M | $3.32M | $6.15M | $7.25M | $3.82M | $5.73M | $3.56M | $2.34M | $4.75M | $5.87M | $4.84M | $7.48M | $7.48M | $7.48M | $22.61M | $22.51M |
| Low Forecast | $3.47M | $3.47M | $3.47M | $3.47M | $5.67M | $3.98M | $4.56M | $4.32M | $5.71M | $3.12M | $2.82M | $2.19M | $1.41M | $1.92M | $2.14M | $2.66M | $4.92M | $5.80M | $3.05M | $4.58M | $2.85M | $1.87M | $3.80M | $4.70M | $3.87M | $5.98M | $5.98M | $5.98M | $15.08M | $15.01M |
| Surprise % | - | - | - | - | - | - | - | - | 1.15% | 2.64% | 2.56% | 3.03% | 4.68% | 3.40% | - | 2.31% | 1.13% | 0.89% | 1.25% | 0.80% | 1.13% | 1.73% | 0.83% | 0.69% | 0.74% | 0.51% | 0.58% | 0.73% | 0.20% | 0.30% |
Celldex Therapeutics's average Quarter SG&A projection for Mar 24 is $4.32M, based on 2 Wall Street analysts, with a range of $4.32M to $4.32M. The forecast indicates a -51.09% fall compared to CLDX last annual SG&A of $8.83M (Dec 23).
Celldex Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 10 | 14 | 8 | 8 | 10 | 13 | 7 | 7 | 9 | 16 | 7 |
| EPS | - | - | - | - | - | - | - | - | $-1.04K | $-0.81 | $-0.65 | $-0.47 | $-0.50 | $-0.53 | - | $-0.46 | $-0.41 | $-0.45 | $-0.35 | $-0.44 | $-0.55 | $-0.39 | $-0.50 | $-0.72 | $-0.36 | $-0.41 | $-0.63 | $-1.83 | $0.70 | $-0.06 |
| Avg Forecast | $-0.80 | $-0.80 | $-0.78 | $-0.77 | $-0.70 | $-0.68 | $-0.59 | $-0.69 | $-0.73 | $-0.68 | $-0.66 | $-0.62 | $-0.59 | $-0.57 | $-0.46 | $-0.45 | $-0.42 | $-0.35 | $-0.40 | $-0.34 | $-0.37 | $-0.36 | $-0.58 | $-0.71 | $-0.90 | $-0.96 | $-1.17 | $-1.14 | $-3.51 | $-2.55 |
| High Forecast | $-0.80 | $-0.80 | $-0.78 | $-0.77 | $-0.70 | $-0.60 | $-0.59 | $-0.69 | $-0.53 | $-0.68 | $-0.66 | $-0.62 | $-0.59 | $-0.57 | $-0.46 | $-0.38 | $-0.36 | $-0.30 | $-0.34 | $-0.30 | $-0.31 | $-0.31 | $-0.50 | $-0.61 | $-0.77 | $-0.82 | $-1.00 | $-0.98 | $-2.81 | $-2.04 |
| Low Forecast | $-0.80 | $-0.80 | $-0.78 | $-0.77 | $-0.70 | $-0.74 | $-0.59 | $-0.69 | $-0.88 | $-0.68 | $-0.66 | $-0.62 | $-0.59 | $-0.57 | $-0.46 | $-0.51 | $-0.48 | $-0.41 | $-0.46 | $-0.39 | $-0.42 | $-0.41 | $-0.66 | $-0.81 | $-1.03 | $-1.10 | $-1.34 | $-1.30 | $-4.21 | $-3.06 |
| Surprise % | - | - | - | - | - | - | - | - | 1413.57% | 1.19% | 0.99% | 0.76% | 0.85% | 0.94% | - | 1.03% | 0.98% | 1.27% | 0.87% | 1.28% | 1.50% | 1.08% | 0.86% | 1.01% | 0.40% | 0.43% | 0.54% | 1.61% | -0.20% | 0.02% |
According to 9 Wall Street analysts, Celldex Therapeutics's projected average Quarter EPS for Mar 19 is $-1.14, with a low estimate of $-1.30 and a high estimate of $-0.98. This represents a -262.86% decrease compared to CLDX previous annual EPS of $0.70 (Sep 18).
Celldex Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| ALXO | ALX Oncology | $2.14 | $24.50 | 1044.86% | Buy |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| BCAB | BioAtla | $1.66 | $5.00 | 201.20% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.79 | $38.80 | 181.36% | Buy |
| EWTX | Edgewise Therapeutics | $19.07 | $48.00 | 151.70% | Buy |
| MGTX | MeiraGTx | $4.29 | $9.00 | 109.79% | Buy |
| SWTX | SpringWorks Therapeutics | $35.58 | $67.33 | 89.24% | Buy |
| KROS | Keros Therapeutics | $55.71 | $105.00 | 88.48% | Buy |
| IMTX | Immatics | $12.19 | $22.00 | 80.48% | - |
| COGT | Cogent Biosciences | $10.55 | $18.50 | 75.36% | Buy |
| TVTX | Travere Therapeutics | $14.35 | $21.60 | 50.52% | Buy |
| CYTK | Cytokinetics | $55.94 | $80.92 | 44.65% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.77 | $70.14 | 32.92% | Buy |
| IDYA | IDEAYA Biosciences | $34.75 | $46.13 | 32.75% | Buy |
| DYN | Dyne Therapeutics | $34.34 | $43.88 | 27.78% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $44.06 | $52.17 | 18.41% | Buy |
| CLDX | Celldex Therapeutics | $41.85 | $49.33 | 17.87% | Buy |
| RNA | Avidity Biosciences | $44.63 | $50.00 | 12.03% | Buy |
| ANAB | AnaptysBio | $36.57 | $36.33 | -0.66% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
CLDX Forecast FAQ
Is Celldex Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Celldex Therapeutics (CLDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of CLDX's total ratings.
What is CLDX's price target?
Celldex Therapeutics (CLDX) average price target is $49.33 with a range of $27 to $63, implying a 17.87% from its last price of $41.85. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Celldex Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CLDX stock, the company can go up by 17.87% (from the last price of $41.85 to the average price target of $49.33), up by 50.54% based on the highest stock price target, and down by -35.48% based on the lowest stock price target.
Can Celldex Therapeutics stock reach $60?
CLDX's highest twelve months analyst stock price target of $63 supports the claim that Celldex Therapeutics can reach $60 in the near future.
What are Celldex Therapeutics's analysts' financial forecasts?
Celldex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.8M (high $4.46M, low $3.47M), average EBITDA is $-20.704M (high $-16.833M, low $-24.903M), average net income is $-148M (high $-139M, low $-156M), average SG&A $20.29M (high $23.79M, low $18.53M), and average EPS is $-2.658 (high $-2.58, low $-2.717). CLDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.6M (high $2.6M, low $2.6M), average EBITDA is $-2.6M (high $-2.6M, low $-2.6M), average net income is $-207M (high $-207M, low $-207M), average SG&A $13.88M (high $13.88M, low $13.88M), and average EPS is $-3.14 (high $-3.14, low $-3.14).
Did the CLDX's actual financial results beat the analysts' financial forecasts?
Based on Celldex Therapeutics's last annual report (Dec 2023), the company's revenue was $6.88M, beating the average analysts forecast of $2.96M by 132.32%. Apple's EBITDA was $-141M, beating the average prediction of $-21.498M by 557.87%. The company's net income was $-141M, missing the average estimation of $-156M by -9.59%. Apple's SG&A was $30.91M, beating the average forecast of $15.82M by 95.39%. Lastly, the company's EPS was $-2.919K, beating the average prediction of $-2.694 by 108253.50%. In terms of the last quarterly report (Dec 2023), Celldex Therapeutics's revenue was $4.13M, beating the average analysts' forecast of $1.44M by 186.59%. The company's EBITDA was $-32.171M, beating the average prediction of $-1.441M by 2131.88%. Celldex Therapeutics's net income was $-50.252M, beating the average estimation of $-48.441M by 3.74%. The company's SG&A was $8.83M, beating the average forecast of $7.7M by 14.74%. Lastly, the company's EPS was $-1.037K, beating the average prediction of $-0.734 by 141257.41%